Abstract
Background COVID-19 is characterized by a rapid change in the patient’s condition, with major changes occurring over a few days. Our aim was to develop and evaluate an emergency system for monitoring patients with COVID-19, which may be useful in hospitals where more severe patients stay in their homes.
Methodology/Principal findings The system consists of the home-based patient unit, which is set up around the patient and the hospital unit, which enables the medical staff to telemonitor the patient’s condition and help to send medical recommendations. The home unit allows the data transmission from the patient to the hospital, which is performed using a cell phone application. The hospital unit includes a virtual instrument developed in LabVIEW® environment that is able to provide a real-time monitoring of the oxygen saturation (SpO2), beats per minute (BPM), body temperature (BT) and peak expiratory flow (PEF). Abnormal events may be fast and automatically identified. After the design details are described, the system is validated by a 30-day home monitoring study in 12 controls and 12 patients with COVID-19 presenting asymptomatic to mild disease. Patients presented reduced SpO2 (p<0.0001) and increased BPM values (p<0.0001). Three patients (25%) presented PEF values between 50 and 80% of the predicted. Three of the 12 monitored patients presented events of desaturation (SpO2<92%). The experimental results were in close agreement with the involved pathophysiology, providing clear evidences that the proposed system can be a useful tool for the remote monitoring of patients with COVID-19.
Conclusions An emergency system for home monitoring of patients with COVID-19 was developed in the current study. The proposed system allowed us to quickly respond to early abnormalities in these patients. This system may contribute to conserve hospital resources for those most in need, while simultaneously enabling early recognition of patients under acute deterioration, requiring urgent assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
LPM, PPFS, BMB, JLMA, LGM, MNB, MRF, RM, RAN, PLM: E-26/010.000166/2020, Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro, FAPERJ, http://www.faperj.br/. PLM: 210.099/2020, Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro, FAPERJ, http://www.faperj.br/. PLM: 409380/2018-0, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, http://www.cnpq.br/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committee of the Pedro Ernesto University Hospital (HUPE) approved the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data will be available from a public repository (Open Science Framework) after acceptance.
